DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



ROSPA - Record on Satisfaction of Patients With Actonel 35 mg Once a Week

Information source: Sanofi
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Osteoporosis

Intervention: Risedronate (Drug)

Phase: Phase 4

Status: Terminated

Sponsored by: Sanofi

Official(s) and/or principal investigator(s):
Jean-Marc Chantelot, MD, Study Director, Affiliation: Sanofi

Summary

To determine the satisfaction of subject with Actonel 35 mg Once a Week in the treatment of post-menopausal osteoporosis. Open, non-controlled, multi-center study.

Clinical Details

Official title: Record on Satisfaction of Patients With Actonel 35 mg Once a Week

Study design: Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Patient satisfaction and compliance

Eligibility

Minimum age: 55 Years. Maximum age: 80 Years. Gender(s): Female.

Criteria:

Inclusion criteria :

- Postmenopausal ambulatory women

- Established osteoporosis

Exclusion criteria:

- History of cancer: basal cell or squamous cell carcinoma-documented 6-month

remission,

- Diagnosis of hypocalcemia, hyperparathyroidism, hyperthyroidism

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Locations and Contacts

Sanofi-Aventis, Natanya, Israel
Additional Information

Starting date: May 2005
Last updated: September 24, 2009

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017